あなたはここにいる:ホーム > お知らせ
06
07
2021
On June 2, 2021, the National Medical Products Administration (NMPA) officially announced that the glucocorticoid drug PA9159 nasal spray was approved for clinical use. The PA9159 developed by Zhejiang Palaatu Pharmaceutical Company (Palaatu) is for seasonal and perennial allergic rhinitis.
05
14
2021
Adhering to "Innovation-Driven, Quality First", Medicilon has established a laboratory research platform focused on evaluating the safety of chemical processes to provide clients with customized, accurate and reliable testing data and safety assessments.
05
07
2021
Medicilon has provided comprehensive support and services for the safety and effectiveness evaluation of various new drugs and vaccines, specifically the research of LNP-mRNA drugs and vaccines, accumulating rich experience. Hence we establish the bioanalysis platform for mRNA vaccines.
04
25
2021
Shanghai Medicilon Inc. recently assigned Dr. Haifeng Yin as the vice president of process chemistry and formulation study, Dr. Baohong Cao as the vice president of pharmacology.
Dr. Chunlin Chen, the founder and CEO of Medicilon, welcomed the two and hoped that their participation will bring new innovation and development momentum to Medicilon, bringing a higher level of industry insight and strategic guidance.
04
19
2021
HG381 is new molecular entity developed by HitGen based on the DNA-encoded compound Library (DEL) technology and small molecule new drug research and development platform.As a leading R&D partner of HitGen, Shanghai Medicilon Inc. (Medicilon) provided preparation R&D services for HG381.